CD274 and hepatocellular carcinoma: Immune checkpoint inhibitor therapy, including PD-1 and PD-L1 inhibitors, have shown clinical benefit in various cancers [2–6], and several studies have shown encouraging clinical activity of anti-PD-1 antibodies in previously treated patients with HCC [7, 8].